| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution.   |
The Motley Fool
October 24, 2005
Brian Gorman |
PAREXEL Gets Squeezed First-quarter results reflect tough competition in the contract research industry. For now, this may be one stock to avoid. |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
January 27, 2011
Seth Jayson |
Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors. |
The Motley Fool
March 20, 2006
Brian Gorman |
Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
The Motley Fool
April 20, 2011
Brandon Glenn |
Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle. |
The Motley Fool
October 31, 2006
Brian Gorman |
Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride. |
The Motley Fool
June 10, 2005
Brian Gorman |
PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
